A BIOCOMPATIBLE NANOPARTICLE-BASED APPROACH TO INHIBITING RENAL ISCHEMIA REPERFUSION INJURY IN MICE BY BLOCKING THROMBOSPONDIN-1 ACTIVITY

Yue Hou,Yanbao Xin,Shuhan Liu,Yong Li,Xiandi Meng,Jialiang Wang,Zhonggao Xu,Tianmeng Sun,Yong-Guang Yang
DOI: https://doi.org/10.1111/ajt.17052
IF: 9.369
2022-01-01
American Journal of Transplantation
Abstract:Thrombospondin-1 (TSP-1) is a key mediator of renal ischemia-reperfusion injury (IRI), a major cause of kidney dysfunction under various disease conditions and a risk factor of renal allograft rejection. In this study, we developed a nanotechnology-based therapy targeting TSP-1 to prevent renal IRI. A biocompatible nanoparticle (NP) capable of specific binding to TSP-1 was prepared by conjugating NPs with TSP-1-binding (LSKL) peptides. LSKL/NPs not only effectively adsorbed recombinant TSP-1 proteins in vitro, but also efficiently neutralized TSP-1 in mice undergoing renal IRI. IRI-induced elevation of TSP-1 in the kidney was significantly inhibited by post-IR treatment with LSKL/NPs, but not free LSKL or NPs. Furthermore, TSP-1 proteins adsorbed on LSKL/NPs were functionally inactive and unable to induce apoptosis in renal tubular epithelial cells. Importantly, LSKL/NPs induced strong protection against renal IRI, as shown by markedly diminished serum creatinine levels and improved histological lesions of the kidney. Thus, LSKL/NPs provide a useful means of depleting and inactivating TSP-1 and a potential therapy for renal IRI.
What problem does this paper attempt to address?